Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5854771 | 0.90 | F2 (0.78) | F2PRSS1 | |
| SCHEMBL7719607 | 0.90 | F2 (0.75) | F2 | |
| Dpoc-4088 SCHEMBL29456568 | 0.88 | F2 (1.00) | F2PRSS1 | |
| SCHEMBL7448367 | 0.88 | F2 (0.83) | F2PRSS1 | |
| Dpoc-4088 SCHEMBL12636557 | 0.88 | F2 (1.00) | F2PRSS1 | |
| SCHEMBL7452924 | 0.88 | F2 (0.83) | F2PRSS1 | |
| SCHEMBL7643508 | 0.88 | F2 (0.84) | F2PRSS1 | |
| Hydrochloric Acid SCHEMBL7448347 | 0.88 | F2 (0.81) | F2PRSS1 | |
| SCHEMBL7455837 | 0.87 | F2 (0.80) | F2PRSS1 | |
| SCHEMBL21067957 | 0.87 | F2 (0.76) | F2PRSS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6462050-B1 | FOR TREATING OR PREVENTING VENOUS, CARDIOGENIC, AND ARTERIAL THROMBOSIS/EMBOLISM, ATHERSCLEROSIS, AND FOR LOWERING PROPENSITY OF DEVICES THAT COME INTO CONTACT WITH BLOOD TO CLOT BLOOD | MERCK & CO., INC. | 2002-10-08 | — | — | US | disclosed |
| US-20020035115-A1 | Thrombin inhibitors | MERCK SHARP & DOHME CORP. | 2002-03-21 | — | — | US | disclosed |
| WO-2002009711-A1 | THROMBIN INHIBITORS | MERCK & CO., INC. (US) | 2002-02-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020035115-A1 | Thrombin inhibitors | TFPI, PLAT, F2 | F2 3/4885PRSS1 55/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.